NR-20201

N/A

Report date: 2026/04/06 20:01:48

Base Information

Drug NameNR-20201
Drug Alias NameAD-MSCs cell therapy同种异体脂肪间充质基质细胞NR-20201
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsIschemic StrokeStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTianjin Tasly Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Tasly Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsIschemic StrokeStroke
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A